IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY)
Copyright © 2024. Publicado por Elsevier España, S.L.U..
OBJECTIVE: the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD).
METHODS: VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD. This study includes IBD patients who have recieved the full vaccination schedule and without previous COVID-19 infection. Seroconversion was set at 260 BAU/mL (centralized determination) and was assessed 6 months after full vaccination. In this subanalysis of the study, we compare the effectivenes of the vaccine between patients treated with mesalazine and patients without treatment.
RESULTS: A total of 124 patients without immunosuppressive therapy were included, of which 32 did not receive any treatment and 92 received only mesalazine. Six months after full vaccination, no significant differences are observed in the mean concentrations of IgG anti-S between both groups. In the multivariate analysis, antibody titers were independently associated with the use of mRNA vaccines and with SARS-CoV-2 infection.
CONCLUSION: Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - (2024) vom: 12. Jan. |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
IMPACTO DE LA MESALAZINA EN LA RESPUESTA A LA VACUNACIÓN CONTRA EL COVID-19 EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. RESULTADOS DE UN ESTUDIO PROSPECTIVO MULTICÉNTRICO DE GETECCU (VACOVEII) |
|---|
| Links: |
|---|
| Themen: |
: SARS-CoV-2 |
|---|
| Anmerkungen: |
Date Revised 14.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.gastrohep.2023.12.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367105098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367105098 | ||
| 003 | DE-627 | ||
| 005 | 20240115232112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2023.12.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM367105098 | ||
| 035 | |a (NLM)38219960 | ||
| 035 | |a (PII)S0210-5705(24)00017-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deza, Diego Casas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY) |
| 246 | 3 | 3 | |a IMPACTO DE LA MESALAZINA EN LA RESPUESTA A LA VACUNACIÓN CONTRA EL COVID-19 EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. RESULTADOS DE UN ESTUDIO PROSPECTIVO MULTICÉNTRICO DE GETECCU (VACOVEII) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Publicado por Elsevier España, S.L.U. | ||
| 520 | |a OBJECTIVE: the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD) | ||
| 520 | |a METHODS: VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD. This study includes IBD patients who have recieved the full vaccination schedule and without previous COVID-19 infection. Seroconversion was set at 260 BAU/mL (centralized determination) and was assessed 6 months after full vaccination. In this subanalysis of the study, we compare the effectivenes of the vaccine between patients treated with mesalazine and patients without treatment | ||
| 520 | |a RESULTS: A total of 124 patients without immunosuppressive therapy were included, of which 32 did not receive any treatment and 92 received only mesalazine. Six months after full vaccination, no significant differences are observed in the mean concentrations of IgG anti-S between both groups. In the multivariate analysis, antibody titers were independently associated with the use of mRNA vaccines and with SARS-CoV-2 infection | ||
| 520 | |a CONCLUSION: Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a : SARS-CoV-2 | |
| 650 | 4 | |a Enfermedad Inflamatoria Intestinal | |
| 650 | 4 | |a GETECCU | |
| 650 | 4 | |a Inflammatory Bowel Disease | |
| 650 | 4 | |a Mesalazina | |
| 650 | 4 | |a Mesalazine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a Vacuna | |
| 700 | 1 | |a Julián Gomara, Ana Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Biota, Eva Caudevilla |e verfasserin |4 aut | |
| 700 | 1 | |a Beltrán, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, Eugeni |e verfasserin |4 aut | |
| 700 | 1 | |a Casbas, Ana Gutiérrez |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Zabana, Yamile |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaro, Lourdes Roc |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Emilio Valverde |e verfasserin |4 aut | |
| 700 | 1 | |a González, Elena García |e verfasserin |4 aut | |
| 700 | 1 | |a Sicilia, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Laredo, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Alcalá Escriche, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Velázquez, Lucia Madero |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Rocío Ferreiro |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Antonia Palmero |e verfasserin |4 aut | |
| 700 | 1 | |a Calafat, Margalida |e verfasserin |4 aut | |
| 700 | 1 | |a Iturria, Saioa Rubio |e verfasserin |4 aut | |
| 700 | 1 | |a Yudego, Irene Moraleja |e verfasserin |4 aut | |
| 700 | 1 | |a Nieto, Yolanda Ber |e verfasserin |4 aut | |
| 700 | 1 | |a Mateo, Sandra García |e verfasserin |4 aut | |
| 700 | 1 | |a Gisbert, Javier P |e verfasserin |4 aut | |
| 700 | 1 | |a Lidón, Raquel Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Alfambra, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Roche, Pilar Corsino |e verfasserin |4 aut | |
| 700 | 1 | |a de Acosta, Manuel Barreiro |e verfasserin |4 aut | |
| 700 | 1 | |a López, Santiago García |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g (2024) vom: 12. Jan. |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2023.12.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 01 | ||